An estimated 3.6 million Medicare beneficiaries could potentially access Wegovy now that the Food and Drug Administration (FDA) approved the drug for reducing the risk of incidents related to cardiovascular disease.
A KFF analysis found that among the 13.7 million people on Medicare diagnosed with obesity, 3.6 million, or roughly 1 in 4, of these beneficiaries also have diagnoses of cardiovascular disease. These potential beneficiaries represent about 7 percent of all those on Medicare.